IPO Premiums
IPO calendar
BMListed

Bio Medica Laboratories Limited

Bookbuilding IPO · NSE

Price band
₹132 - ₹139
Lot size
1,000 shares
Issue amount
₹52.43 cr
Total subscription
2.31×
Current price₹119.2
Listing price ₹111.2
Watch live price ↗
Opens
21 May 2026
Closes
25 May 2026
Allotment
26 May 2026
Listing
29 May 2026

Offer at a glance

Issue overview

Issue size
37,72,000 shares
Face value
₹10 per share
Minimum investment
₹1,32,000
Fresh issue
₹47.19 cr
Offer for sale
₹5.24 cr
Registrar
Skyline Financial Services Private Limited
Listing exchange
NSE
Maximum investment
₹1,39,000
Issue type
Bookbuilding IPO
Shares before issue
91,80,001
Shares after issue
1,25,75,001

Lot sizes

CategoryLotsSharesAmount
Retail22,000₹2,78,000
sHNI33,000₹4,17,000
bHNI88,000₹11,12,000

Share reservation

QIB0.95%
HNI46.53%
RETAIL47.51%
Market Maker5.01%

Subscription & GMP

Subscription by category

Total subscribed2.31×

Reported 25 May 2026

QIB15.94×
NIB1.41×
RETAIL2.92×
HNIs(10L+)1.02×
HNIs(2-10L)2.19×

GMP history

-7-3128 May: ₹-7
28 May₹-728 May

Day-wise demand

21 May0.72×
22 May1.06×
25 May2.31×

Application-wise demand

CategoryReserved applicationsApplied applications
QIB06
NIB0457
RETAIL8962,614
HNIs(10L +)39035
HNIs (2-10L)195422

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
QIBs0.57.98
FIIs07.98
RETAIL24.9172.67
HNIs 2+8.1317.82
HNIs 10+16.2616.58

Financial performance

Company financials

In Crores · Reported periods may include interim results.

Revenue & profitIn Crores
010203040Mar-23 · Revenue: 16.24Mar-23 · Profit after tax: 0.33Mar-23Mar-24 · Revenue: 15.34Mar-24 · Profit after tax: 2.49Mar-24Mar-25 · Revenue: 38.32Mar-25 · Profit after tax: 9.79Mar-25Nov-25 · Revenue: 28.62Nov-25 · Profit after tax: 8.66Nov-25
RevenueProfit after tax

Key performance indicators

MetricNov-25Mar-25Mar-24Mar-23
EPS9.4410.672.720.36
ROE54.4199.5967.7413.92
ROCE23.2448.229.9210.16
RONW0000
PRE IPO(PE)013.0300
POST IPO(PE)13.45000

Values and labels as reported in the issue data.

Peer comparison

CompanyP/E(X)CMP* (₹)Face value (₹)NAV/Share (₹)RONW(%)EPS (Basic) (₹)
Bio Medica Laboratories Limited0010.0016.0599.5910.67
Zenotech Laboratories Limited047.9510.0015.766.010.92
Shukra Pharmaceuticals Limited47.5733.541.001.4315.900.22

Company information

Company profile

Bio Medica Laboratories is a pharmaceutical company engaged in manufacturing parenteral formulations for both human and veterinary healthcare segments. The company produces a wide range of ethical drugs, generic medicines, and OTC products, primarily in liquid and dry powder injectable forms. Its portfolio includes 58 liquid injectables and 15 dry powder injectable products available in single-dose and multi-dose formats. Operating on a B2B contract manufacturing model, the company develops customized formulations according to client requirements. Supported by GMP and GLP certifications, Bio Medica runs two manufacturing facilities in Indore, Madhya Pradesh, focusing on quality production and pharmaceutical formulation development.

Strengths

  • Diversified Injectable Portfolio: Offers a wide range of liquid and dry powder injectables for various therapeutic needs.
  • Strong Contract Manufacturing: B2B-focused model supports customized formulation development for pharmaceutical clients.
  • Experienced Management & Workforce: Industry-experienced teams support efficient manufacturing and quality standards.

Risk factors

  • Regulatory Compliance Risk: Previous suspension of operations at a manufacturing unit due to non-compliance may affect reputation and business operations.
  • Customer Concentration Risk: Dependence on a limited number of clients may impact financial performance if key customers are lost.
  • Quality Control & Manufacturing Risk: Product defects or quality issues may lead to litigation, regulatory action, and reputational damage.

Promoters

Mr. Mukesh Mehta

Mr. Pradeep Mehta

Registrar & documents

Lead manager

Narnolia Financial Services Limited

Registered office

Plot No. 11B-11C, Sector-E, Sanwer Road Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh, 452015

+91 7314102751

[email protected]Company website ↗

Frequently Asked Questions

What is Bio Medica Laboratories IPO GMP today?

As of today, Bio Medica Laboratories IPO Grey Market Premium (GMP) is reported at −₹7 per share. Based on the upper price band of ₹139, the estimated listing price is ₹132 (-5.0% expected discount). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.

What is the lot size and minimum investment for Bio Medica Laboratories IPO?

The minimum bid lot size for Bio Medica Laboratories IPO is 1,000 shares. At the cut-off price of ₹139 per share, retail investors need a minimum application amount of ₹1,39,000 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).

When will Bio Medica Laboratories IPO allotment status be announced?

The allotment status for Bio Medica Laboratories IPO is scheduled to be finalized on 26 May 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Skyline Financial Services Private Limited's official portal or via BSE/NSE allotment portals.

How can I check Bio Medica Laboratories IPO allotment status online by PAN?

To check Bio Medica Laboratories IPO allotment status: 1) Visit the registrar portal (Skyline Financial Services Private Limited) or the BSE IPO allotment page. 2) Select 'Bio Medica Laboratories Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.

Explore More IPO Analysis & Live Tools

Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.

Regulatory Disclaimer: Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and does not represent a stock exchange transaction, guarantee, or investment advice. IPO Premiums is an informational and research portal and is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before applying for any IPO.